OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	76
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	66
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study	57
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma	45
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	36
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	31
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar	31
Imaging of brain metastases treated with immune checkpoint inhibitors	31
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So Â€˜Pureâ€™	28
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	27
Postvaccination immune-mediated hepatitis: what do we really know?	25
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	25
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?	21
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey	20
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	17
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	16
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression	15
Immunotherapy for Gastric Cancer: A 2021 Update	15
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review	15
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	15
Immune Checkpoint Inhibitors Use and Effects on Prognosis of COVID-19 Infection: A Systematic Review and Meta-Analysis	14
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	13
Adherence, persistence and treatment switching in psoriasis	13
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors	13
Nivolumab induced discolouration of the tongue: a case report	12

Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis	12
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	12
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	12
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	12
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	12
Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes	12
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	12
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	12
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	12
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review	12
Efficacy of mIte Allergen Immunotherapy in Allergic Rhinitis and the Immune Synergistic Effect on Cross-Allergens	11
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	11
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review	10
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	10
Deucravacitinib in Moderate-To-Severe Psoriasis	10
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	10
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	10
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	10
Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases	10
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	10
Liquid biopsy for guiding breast cancer immunotherapy	10
Immune Checkpoint Inhibitors in Cholangiocarcinoma	10
Current Immunosuppression Strategies in Pediatric Heart Transplant	10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	10
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	10
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	10
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	9
Effectiveness of COVID-19 Vaccines Against Omicron Variant	9
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	9
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	9
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	9
Integrase inhibitors: current protagonists in antiretroviral therapy	9
Immune-Related Gigantomastia: A Case Study	9
A Summertime Pause in Immunoglobulin Replacement Therapy: A Prospective Real-World Analysis	9
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer	9
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	8
Abrocitinib for the Treatment of Atopic Dermatitis	8
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	8
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	8
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	8
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	8
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	8
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	8
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	8
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	8

A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	8
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	8
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	8
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	7
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	7
Pembrolizumab in an HIV-infected patient with glioblastoma	7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Immunotherapies for prevention and treatment of type 1 diabetes	7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	7
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	7
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	7
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	7
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy	7
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	7
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	7
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	7
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	6
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	6
Peptide–MHC Complexes: Dressing up to Manipulate T Cells Against Autoimmunity and Cancer	6
Targeting the Tumor Microenvironment of Ewing Sarcoma	6
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody	6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy	6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	6
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
Anaphylaxis to Tocilizumab in Patients with Rheumatic Disease	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	6
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Tsunami of Immunotherapies in the Management of Esophageal Cancer	5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	5
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?	5
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	5
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease	5
Pembrolizumab: A New Standard of Care in Metastatic Colorectal Cancer	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	5
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis	5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	5
Bimekizumab for The Treatment of Psoriasis	5
Successful Use of Secukinumab in Two Melanoma Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthropathy	5
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer	5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	5
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review	5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event	5
Mirna Profiles Change During Grass Pollen Immunotherapy Irrespective of Clinical Outcome	5
Multicenter Real-World Experience with Epinephrine 0.5 mg Dosing for Anaphylaxis with Allergen Immunotherapy	5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors	5